Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections

Background: Although the prognostic value of Ki67 in breast cancer is well documented, using optimal cut-points for patient stratification, reproducibility of the scoring and interpretation of the results remain a matter of debate particularly when using Tissue Microarrays (TMAs). This study aims to...

Full description

Bibliographic Details
Main Authors: Muftah, Abir A., Aleskandarany, Mohammed A., Al-kaabi, Methaq M., Sonbul, Sultan N., Diez-Rodriguez, Maria, Nolan, Christopher C., Caldas, Carlos, Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Format: Article
Published: Springer 2017
Subjects:
Online Access:https://eprints.nottingham.ac.uk/42543/
_version_ 1848796510921162752
author Muftah, Abir A.
Aleskandarany, Mohammed A.
Al-kaabi, Methaq M.
Sonbul, Sultan N.
Diez-Rodriguez, Maria
Nolan, Christopher C.
Caldas, Carlos
Ellis, Ian O.
Rakha, Emad A.
Green, Andrew R.
author_facet Muftah, Abir A.
Aleskandarany, Mohammed A.
Al-kaabi, Methaq M.
Sonbul, Sultan N.
Diez-Rodriguez, Maria
Nolan, Christopher C.
Caldas, Carlos
Ellis, Ian O.
Rakha, Emad A.
Green, Andrew R.
author_sort Muftah, Abir A.
building Nottingham Research Data Repository
collection Online Access
description Background: Although the prognostic value of Ki67 in breast cancer is well documented, using optimal cut-points for patient stratification, reproducibility of the scoring and interpretation of the results remain a matter of debate particularly when using Tissue Microarrays (TMAs). This study aims to assess Ki67 expression assessed on TMAs and their matched whole tissue sections (WTS). Moreover, whether the cut-off used for WTS is reproducible on TMA in BC molecular classes and the association between Ki67 expression cut-off, assessed on TMAs and WTS, and clinicopathological parameters and patient outcome will also be tested. Method: A large series (n=707) of primary invasive breast tumours were immunostained for Ki67 using both TMA and WTS and assessed as percentage staining and correlated with each other, clinicopathological parameters and patient outcome. In addition, MKI67 mRNA expression was correlated with Ki67 protein levels on WTS and TMAs in a subset of cases included in the METABRIC study. Results: There was moderate concordance in Ki67 expression between WTS and TMA when analysed as a continuous variable (Intraclass correlation coefficient=0.61) and low concordance when dichotomised (kappa-value=0.3). TMA showed low levels of Ki67 with mean percentage of expression 35% 22% on WTS and TMA, respectively. MKI67 mRNA expression was significantly correlated with protein expression determined on WTS (Spearman Correlation, r=0.52) and to a lesser extent on TMA (r=0.34) (p<0.001). Regarding prediction of patient outcome, statistically significant differences were detected upon stratification of patients with tumours expressing Ki67 at 10%, 15%, 20%, 25% or 30% in TMA. Using TMA, ≥20 % Ki67 provided the best prognostic cut-off particularly in triple negative and HER2 positive classes. Conclusion: Ki67 expression in breast cancer can be evaluated using TMA although different cutpoints are required to emulate results from WTS. A cut-off of ≥ 20 % for Ki67 expression in BC provides the best prognostic correlations when TMAs are used.
first_indexed 2025-11-14T19:49:08Z
format Article
id nottingham-42543
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:49:08Z
publishDate 2017
publisher Springer
recordtype eprints
repository_type Digital Repository
spelling nottingham-425432024-08-15T15:23:30Z https://eprints.nottingham.ac.uk/42543/ Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections Muftah, Abir A. Aleskandarany, Mohammed A. Al-kaabi, Methaq M. Sonbul, Sultan N. Diez-Rodriguez, Maria Nolan, Christopher C. Caldas, Carlos Ellis, Ian O. Rakha, Emad A. Green, Andrew R. Background: Although the prognostic value of Ki67 in breast cancer is well documented, using optimal cut-points for patient stratification, reproducibility of the scoring and interpretation of the results remain a matter of debate particularly when using Tissue Microarrays (TMAs). This study aims to assess Ki67 expression assessed on TMAs and their matched whole tissue sections (WTS). Moreover, whether the cut-off used for WTS is reproducible on TMA in BC molecular classes and the association between Ki67 expression cut-off, assessed on TMAs and WTS, and clinicopathological parameters and patient outcome will also be tested. Method: A large series (n=707) of primary invasive breast tumours were immunostained for Ki67 using both TMA and WTS and assessed as percentage staining and correlated with each other, clinicopathological parameters and patient outcome. In addition, MKI67 mRNA expression was correlated with Ki67 protein levels on WTS and TMAs in a subset of cases included in the METABRIC study. Results: There was moderate concordance in Ki67 expression between WTS and TMA when analysed as a continuous variable (Intraclass correlation coefficient=0.61) and low concordance when dichotomised (kappa-value=0.3). TMA showed low levels of Ki67 with mean percentage of expression 35% 22% on WTS and TMA, respectively. MKI67 mRNA expression was significantly correlated with protein expression determined on WTS (Spearman Correlation, r=0.52) and to a lesser extent on TMA (r=0.34) (p<0.001). Regarding prediction of patient outcome, statistically significant differences were detected upon stratification of patients with tumours expressing Ki67 at 10%, 15%, 20%, 25% or 30% in TMA. Using TMA, ≥20 % Ki67 provided the best prognostic cut-off particularly in triple negative and HER2 positive classes. Conclusion: Ki67 expression in breast cancer can be evaluated using TMA although different cutpoints are required to emulate results from WTS. A cut-off of ≥ 20 % for Ki67 expression in BC provides the best prognostic correlations when TMAs are used. Springer 2017-07-31 Article PeerReviewed Muftah, Abir A., Aleskandarany, Mohammed A., Al-kaabi, Methaq M., Sonbul, Sultan N., Diez-Rodriguez, Maria, Nolan, Christopher C., Caldas, Carlos, Ellis, Ian O., Rakha, Emad A. and Green, Andrew R. (2017) Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Research and Treatment, 164 (2). pp. 341-348. ISSN 1573-7217 Ki67 Breast Cancer Immunohistochemistry Prognosis METABRIC https://link.springer.com/article/10.1007%2Fs10549-017-4270-0 doi:10.1007/s10549-017-4270-0 doi:10.1007/s10549-017-4270-0
spellingShingle Ki67
Breast Cancer
Immunohistochemistry
Prognosis
METABRIC
Muftah, Abir A.
Aleskandarany, Mohammed A.
Al-kaabi, Methaq M.
Sonbul, Sultan N.
Diez-Rodriguez, Maria
Nolan, Christopher C.
Caldas, Carlos
Ellis, Ian O.
Rakha, Emad A.
Green, Andrew R.
Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
title Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
title_full Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
title_fullStr Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
title_full_unstemmed Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
title_short Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
title_sort ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
topic Ki67
Breast Cancer
Immunohistochemistry
Prognosis
METABRIC
url https://eprints.nottingham.ac.uk/42543/
https://eprints.nottingham.ac.uk/42543/
https://eprints.nottingham.ac.uk/42543/